C12N 2810/40
Vectors comprising a peptide as targeting moiety
Official title: Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
C12N2810/40 (Vectors comprising a peptide as targeting moiety) appears on 161 US grants and 249 published applications in this corpus.
Search patents in C12N- Granted patents
- 161
- Published applications
- 249
- Assignees
- 140
- Inventors
- 520
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 5 | 0 |
| 1999 | 10 | 0 |
| 2000 | 8 | 0 |
| 2001 | 9 | 2 |
| 2002 | 9 | 15 |
| 2003 | 7 | 18 |
| 2004 | 8 | 9 |
| 2005 | 5 | 13 |
| 2006 | 6 | 14 |
| 2007 | 4 | 6 |
| 2008 | 2 | 7 |
| 2009 | 3 | 8 |
| 2010 | 3 | 11 |
| 2011 | 3 | 6 |
| 2012 | 4 | 9 |
| 2013 | 4 | 6 |
| 2014 | 9 | 11 |
| 2015 | 5 | 17 |
| 2016 | 3 | 6 |
| 2017 | 8 | 8 |
| 2018 | 9 | 12 |
| 2019 | 6 | 9 |
| 2020 | 7 | 11 |
| 2021 | 2 | 5 |
| 2022 | 5 | 6 |
| 2023 | 3 | 5 |
| 2024 | 5 | 10 |
| 2025 | 6 | 12 |
| 2026 | 2 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-tumor composition12 May 2026US 12,622,936 B2Genemedicine Co., Ltd.
- Methods for improved homologous recombination and compositions thereof28 Apr 2026US 12,612,650 B2Life Technologies Corporation
- AAV vector variants for ocular gene delivery30 Dec 2025US 12,509,705 B2Medizinische Hochschule Hannover
- Integration of mesa receptors and promotors to implement customized cellular function28 Oct 2025US 12,454,689 B2Northwestern University
- Adenosomes7 Oct 2025US 12,435,110 B2Erasmus University Medical Center Rotterdam
- Targeting aav capsids, methods of manufacturing and using same8 Oct 2026US 2026/0308615 A1REGENXBIO Inc.
- An aav2-vector variant for targeted transfer of genes3 Sep 2026US 2026/0258448 A1Universitaetsklinikum Hamburg-Eppendorf
- Cell membrane-penetrating peptide for conjugation20 Aug 2026US 2026/0242827 A1AGC Inc.
- An aav9 capsid variant for targeted gene transfer6 Aug 2026US 2026/0224742 A1Universitaetsklinikum Hamburg-Eppendorf
- Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same23 Jul 2026US 2026/0207773 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Hybrid adenovirus-AAV virus and methods of use thereof311US 5,871,982 AThe Trustees of the University of Pennsylvania · 1999
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Targeting adenovirus with use of constrained peptide motifs158US 5,846,782 AGenVec, Inc. · 1998
- Penton base protein and methods of using same136US 5,559,099 AGenVec, Inc. · 1996